Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06960954

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Official title: Prothrombin Induced by Vitamin K Absence II (PIVKA-II) Serum Level as a Predictor for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

116

Start Date

2025-01-15

Completion Date

2025-12-31

Last Updated

2025-05-07

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Prothrombin induced by vitamin K absence II (PIVKA-II)

Serum PIVKA-II level will be measured in HCC patients with and without PVTT.

Locations (1)

Tanta University Hospitals

Tanta, Gharbyea, Egypt